BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 16598425)

  • 21. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
    Primeau V; Raftopoulos C; Maiter D
    Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pituitary apoplexy within a macroprolactinoma.
    Watt A; Pobereskin L; Vaidya B
    Nat Clin Pract Endocrinol Metab; 2008 Nov; 4(11):635-41. PubMed ID: 18797434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical presentation and response to therapy in patients with massive prolactin hypersecretion.
    Mascarell S; Sarne DH
    Pituitary; 2007; 10(1):95-101. PubMed ID: 17308959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Giant prolactinomas: the therapeutic approach.
    Moraes AB; Silva CM; Vieira Neto L; Gadelha MR
    Clin Endocrinol (Oxf); 2013 Oct; 79(4):447-56. PubMed ID: 23662975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Approach to the Patient With Prolactinoma.
    Auriemma RS; Pirchio R; Pivonello C; Garifalos F; Colao A; Pivonello R
    J Clin Endocrinol Metab; 2023 Aug; 108(9):2400-2423. PubMed ID: 36974474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Selection of management tactics in treatment of giant prolactin-secreting pituitary adenomas].
    Astaf'eva LI; Kadashev BA; Kalinin PL; Kutin MA; Faĭzullaev RB; Sidneva IuG; Tenedieva VD; Tropinskaia OF
    Zh Vopr Neirokhir Im N N Burdenko; 2009; (2):23-8; discussion 28-9. PubMed ID: 19569545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prolactinoma].
    Glezer A; Bronstein MD
    Arq Bras Endocrinol Metabol; 2014 Mar; 58(2):118-23. PubMed ID: 24830588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nephrotic-range proteinuria in a patient with a giant prolactinoma.
    Heras M; Iglesias P; Fernández-Reyes MJ; Sánchez R; Jiménez MJ; Muñoz H; Tajada P; Duarte J
    Am J Kidney Dis; 2008 Jun; 51(6):1025-8. PubMed ID: 18455849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Atypical presentation of a giant prolactinoma in a 15-year-old boy].
    Vaiani E; Morales C; Soto F; Blanco Y; Rugilo C; Ciaccio M; Belgorosky A
    Arch Argent Pediatr; 2018 Apr; 116(2):e325-e330. PubMed ID: 29557627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Macroprolactinomas: longitudinal assessment of biochemical and imaging therapeutic responses.
    Araújo C; Marques O; Almeida R; Santos MJ
    Endocrine; 2018 Nov; 62(2):470-476. PubMed ID: 30088141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Macroadenoma of the pituitary gland with moderate hyperprolactinaemia].
    Harms E; Siggelkow H; Buchfelder M; Saeger W; Hüfner M
    Dtsch Med Wochenschr; 2003 Mar; 128(13):667-70. PubMed ID: 12660899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Current diagnosis and treatment of hyperprolactinemia].
    Melgar V; Espinosa E; Sosa E; Rangel MJ; Cuenca D; Ramírez C; Mercado M
    Rev Med Inst Mex Seguro Soc; 2016; 54(1):111-21. PubMed ID: 26820213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic evaluation of hyperprolactinemia.
    Biller BM
    J Reprod Med; 1999 Dec; 44(12 Suppl):1095-9. PubMed ID: 10649817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy.
    Cackett P; Eunson G; Bath L; Mulvihill A
    Future Oncol; 2012 Dec; 8(12):1621-6. PubMed ID: 23231524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma.
    Hong JW; Lee MK; Kim SH; Lee EJ
    Endocrine; 2010 Feb; 37(1):140-7. PubMed ID: 20963563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Giant prolactinomas: clinical manifestations and outcomes of 16 Arab cases.
    Almalki MH; Buhary B; Alzahrani S; Alshahrani F; Alsherbeni S; Alhowsawi G; Aljohani N
    Pituitary; 2015 Jun; 18(3):405-9. PubMed ID: 25062894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma.
    Cho EH; Lee SA; Chung JY; Koh EH; Cho YH; Kim JH; Kim CJ; Kim MS
    J Korean Med Sci; 2009 Oct; 24(5):874-8. PubMed ID: 19794986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contemporary management of prolactinomas.
    Liu JK; Couldwell WT
    Neurosurg Focus; 2004 Apr; 16(4):E2. PubMed ID: 15191331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Hyperprolactinemia unrelated to prolactinoma].
    Krysiak R; Okopień B
    Wiad Lek; 2014; 67(2 Pt 1):101-11. PubMed ID: 25764785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.